HomeCompareGILD vs GE

GILD vs GE: Dividend Comparison 2026

GILD yields 2.34% · GE yields 0.57%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GE wins by $832.4K in total portfolio value· pulled ahead in Year 4
10 years
GILD
GILD
● Live price
2.34%
Share price
$136.34
Annual div
$3.19
5Y div CAGR
17.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$1,614.90
Full GILD calculator →
GE
GE
● Live price
0.57%
Share price
$273.25
Annual div
$1.55
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$861.6K
Annual income
$643,604.54
Full GE calculator →

Portfolio growth — GILD vs GE

📍 GE pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGILDGE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GILD + GE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GILD pays
GE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GILD
Annual income on $10K today (after 15% tax)
$198.88/yr
After 10yr DRIP, annual income (after tax)
$1,372.67/yr
GE
Annual income on $10K today (after 15% tax)
$48.22/yr
After 10yr DRIP, annual income (after tax)
$547,063.86/yr
At 15% tax rate, GE beats the other by $545,691.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GILD + GE for your $10,000?

GILD: 50%GE: 50%
100% GE50/50100% GILD
Portfolio after 10yr
$445.4K
Annual income
$322,609.72/yr
Blended yield
72.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GILD right now

GILD
Analyst Ratings
37
Buy
20
Hold
1
Sell
Consensus: Buy
Price Target
$158.71
+16.4% upside vs current
Range: $105.00 — $180.00
Altman Z
4.1
Piotroski
8/9
GE
Analyst Ratings
23
Buy
11
Hold
Consensus: Buy
Price Target
$391.50
+43.3% upside vs current
Range: $374.00 — $425.00
Altman Z
3.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GILD buys
0
GE buys
0
No recent congressional trades found for GILD or GE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGILDGE
Forward yield2.34%0.57%
Annual dividend / share$3.19$1.55
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR17.3%100%
Portfolio after 10y$29.1K$861.6K
Annual income after 10y$1,614.90$643,604.54
Total dividends collected$7.6K$822.3K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$158.71$391.50

Year-by-year: GILD vs GE ($10,000, DRIP)

YearGILD PortfolioGILD Income/yrGE PortfolioGE Income/yrGap
1$10,974$274.45$10,813$113.45+$161.00GILD
2$12,073$330.19$11,800$229.30+$273.00GILD
3$13,316$398.20$13,093$467.70+$223.00GILD
4← crossover$14,730$481.49$14,980$970.04$250.00GE
5$16,345$583.87$18,103$2,074.42$1.8KGE
6$18,199$710.26$24,056$4,685.79$5.9KGE
7$20,340$866.96$37,379$11,638.62$17.0KGE
8$22,826$1,062.22$73,797$33,802.35$51.0KGE
9$25,731$1,306.80$203,705$124,741.80$178.0KGE
10$29,147$1,614.90$861,569$643,604.54$832.4KGE

GILD vs GE: Complete Analysis 2026

GILDHealthcare

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Full GILD Calculator →

GEStock

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the Commercial Engines & Services and Defense & Propulsion Technologies segments. The Commercial Engines & Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense & Propulsion Technologies segment offers defense engines and critical aircraft systems. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

Full GE Calculator →
📬

Get this GILD vs GE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GILD vs SCHDGILD vs JEPIGILD vs OGILD vs KOGILD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.